Grace Halsey

Sales of e-cigarettes in the US jumped by 46% from 2020-2022; rapid market shifts beg coordinated restrictions to protect public health, says the CDC.

Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.

ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.

ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.

ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.

ADA 2023: Among survodutide-treated participants in a phase 2 study, more than half lost more than 50% of baseline bodyweight, reported PI Carel le Roux, MBChB, PhD.

ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.

SGLT-2 inhibitors show broad cardiometabolic efficacy; colchicine approved for CV inflammation, astronomical diabetes rates; plus 2 more quotes of note.

Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.

ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.

SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.

Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.

The 2 SGLT-2 inhibitor-based medications are the first in the class to be approved for pediatric T2D and provide a much needed additional oral treatment option for the population.

Higher scores on a healthy lifestyle index were associated with significantly reduced risk of incident CVD among women aged 50-79 years with BMI between 18.5 and 25.0.

Colchicine 0.5 mg is associated with reduction in a wide range of CV events in patients already on statin therapy, supporting the long-held "anti-inflammatory" hypothesis.

ENDO 2023. In older men with hypogonadism and CVD, there was no difference in incident CVD between those taking testosterone and those taking placebo.

Ozempic impact on patients, clinicians; bempedoic acid comparable to statins; hypertension risk upped with oral estrogen HT; and 2 more quotes of note.

ENDO 2023: Treatment with bempedoic acid was found comparable to statin therapy in an analysis of the CLEAR Outcomes trial based on CTT Collaboration methodology.

ENDO 2023. The pattern of intermittent fasting improved glycemic measures in a weight-independent fashion after just 7 days, according to the study abstract.

Acknowledging the historical harm caused by sole reliance on the measure for decisions in clinical practice, the AMA urges clinicians to incorporate other valid measures.

The FDA advisory committee will review all current surveillance data and recommend which strain/s to include in updated COVID-19 vaccines for the 2023-2024 vaccination campaign.

Oral estrogen hormone therapy was more likely to result in incident hypertension than transdermal or vaginal formulations in this large prospective population-based study.

Increased levels of lipoprotein(a) significantly and independently predicted recurrent CHD events in adults aged 60 years and older, report study authors.

Mean time in range increased by ~10% and time above range decreased by 8.1% in study participants taking as few as a single antihyperglycemic medication.

FDA fast tracks triple-threat antithrombotic, dangers of faux semaglutide online, a guide to neurologic sequelae of COVID-19, plus 2 more reviews of note.

Prescriptions for continuous glucose monitoring for patients with T2D are increasing, a new study finds, and the authors report on characteristics of new CGM users.

Reduced risk for 10 different cancers was reported among patients with diabetes treated with SGLT2 inhibitors compared with those not treated.

Primary care clinicians will often be the first challenged to recognize neurologic sequelae of COVID-19; here's how to maximize short visits to assess long COVID.

Compounded versions of semaglutide, often sold online, may contain salt versions of the molecule and are not evaluated by the FDA for safety or efficacy.

Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.